Kölbeck, Karl
Karolinska University Hospital
2 papers on CoChat
Most cited papers
- Verified
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 1,183
- Verified
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., et al. (2017) · Annals of Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 524
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free